Evaluation of economic burden with biologic treatments in Crohn's disease patients: A mirror image study using an insurance database in Japan.

Biologics are recommended in Japan to treat moderate to severe Crohn's Disease (CD). Although CD is associated with high direct costs in Japan, updated information after ustekinumab's approval is unavailable. We aimed to evaluate the healthcare resource utilization (HRU) and associated dir...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Celine Miyazaki, Nagano Katsumasa, Kuan Chih Huang, Yan Fang Liu
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/eed567d2c6054272be60fc9f1dab3d8e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:eed567d2c6054272be60fc9f1dab3d8e
record_format	dspace
spelling	oai:doaj.org-article:eed567d2c6054272be60fc9f1dab3d8e2021-12-02T20:06:49ZEvaluation of economic burden with biologic treatments in Crohn's disease patients: A mirror image study using an insurance database in Japan.1932-620310.1371/journal.pone.0254807https://doaj.org/article/eed567d2c6054272be60fc9f1dab3d8e2021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0254807https://doaj.org/toc/1932-6203Biologics are recommended in Japan to treat moderate to severe Crohn's Disease (CD). Although CD is associated with high direct costs in Japan, updated information after ustekinumab's approval is unavailable. We aimed to evaluate the healthcare resource utilization (HRU) and associated direct costs from the payer's perspective in Japan. Claims data (2010-2018) were retrospectively analyzed to identify patients with CD. HRU and associated costs were evaluated for 12 months before and after biologic initiation and followed-up till 36 months post-initiation. Outcomes were reported using descriptive statistics. Among the included patients (n = 3,496), 1,783 were on biologics and 1,713 were on non-biologics. Mean (SD) age was 36.4 (13.2) years and patients were predominantly male (76.1%). Patients aged 18-39 years were affected with CD the most (55.3%). Biologic initiation was associated with a reduction in inpatient stay, length of stay, outpatient visits, and associated costs; and an increase in pharmacy costs and total costs after 12 months. Extended follow-up showed a decreasing trend in HRU and costs till 24 months but an increase after 36 months. These findings demonstrated reduction in clinical burden and slight increase in economic burden with biologics. However, indirect costs also need to be evaluated.Celine MiyazakiNagano KatsumasaKuan Chih HuangYan Fang LiuPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 7, p e0254807 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Celine Miyazaki Nagano Katsumasa Kuan Chih Huang Yan Fang Liu Evaluation of economic burden with biologic treatments in Crohn's disease patients: A mirror image study using an insurance database in Japan.
description	Biologics are recommended in Japan to treat moderate to severe Crohn's Disease (CD). Although CD is associated with high direct costs in Japan, updated information after ustekinumab's approval is unavailable. We aimed to evaluate the healthcare resource utilization (HRU) and associated direct costs from the payer's perspective in Japan. Claims data (2010-2018) were retrospectively analyzed to identify patients with CD. HRU and associated costs were evaluated for 12 months before and after biologic initiation and followed-up till 36 months post-initiation. Outcomes were reported using descriptive statistics. Among the included patients (n = 3,496), 1,783 were on biologics and 1,713 were on non-biologics. Mean (SD) age was 36.4 (13.2) years and patients were predominantly male (76.1%). Patients aged 18-39 years were affected with CD the most (55.3%). Biologic initiation was associated with a reduction in inpatient stay, length of stay, outpatient visits, and associated costs; and an increase in pharmacy costs and total costs after 12 months. Extended follow-up showed a decreasing trend in HRU and costs till 24 months but an increase after 36 months. These findings demonstrated reduction in clinical burden and slight increase in economic burden with biologics. However, indirect costs also need to be evaluated.
format	article
author	Celine Miyazaki Nagano Katsumasa Kuan Chih Huang Yan Fang Liu
author_facet	Celine Miyazaki Nagano Katsumasa Kuan Chih Huang Yan Fang Liu
author_sort	Celine Miyazaki
title	Evaluation of economic burden with biologic treatments in Crohn's disease patients: A mirror image study using an insurance database in Japan.
title_short	Evaluation of economic burden with biologic treatments in Crohn's disease patients: A mirror image study using an insurance database in Japan.
title_full	Evaluation of economic burden with biologic treatments in Crohn's disease patients: A mirror image study using an insurance database in Japan.
title_fullStr	Evaluation of economic burden with biologic treatments in Crohn's disease patients: A mirror image study using an insurance database in Japan.
title_full_unstemmed	Evaluation of economic burden with biologic treatments in Crohn's disease patients: A mirror image study using an insurance database in Japan.
title_sort	evaluation of economic burden with biologic treatments in crohn's disease patients: a mirror image study using an insurance database in japan.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/eed567d2c6054272be60fc9f1dab3d8e
work_keys_str_mv	AT celinemiyazaki evaluationofeconomicburdenwithbiologictreatmentsincrohnsdiseasepatientsamirrorimagestudyusinganinsurancedatabaseinjapan AT naganokatsumasa evaluationofeconomicburdenwithbiologictreatmentsincrohnsdiseasepatientsamirrorimagestudyusinganinsurancedatabaseinjapan AT kuanchihhuang evaluationofeconomicburdenwithbiologictreatmentsincrohnsdiseasepatientsamirrorimagestudyusinganinsurancedatabaseinjapan AT yanfangliu evaluationofeconomicburdenwithbiologictreatmentsincrohnsdiseasepatientsamirrorimagestudyusinganinsurancedatabaseinjapan
_version_	1718375396432412672

Evaluation of economic burden with biologic treatments in Crohn's disease patients: A mirror image study using an insurance database in Japan.

Ejemplares similares